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would our message need to change once more?  Here are 
the facts: hepatitis C virus is common among Americans 
born between 1945 and 1965. A current Centers for 
Disease Control and Prevention factsheet asserts that 
most people infected with hepatitis C virus are unaware 
of their diagnosis,3 despite aggressive campaigns since 
2012 to ﬁ nd cases.  Let’s just go ahead and test our baby 
boomers. 
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Long-term surveillance of the eﬀ ect of PCV13: the future 
challenge in Africa
Pneumococcal infections are a leading cause of 
morbidity and mortality in children. In Africa, the 
greatest burden of pneumococcal disease and most 
associated deaths occur in children younger than 
5 years.1 In 2008, this continent still accounted for 
more than half of the 541 000 deaths caused by 
pneumococcal disease in this age group.2 
The eﬀ ectiveness of the seven-valent pneumococcal 
conjugate vaccine (PCV7) has been shown in many 
countries—the incidence of invasive pneumococcal 
disease has fallen in all age groups, especially in 
children younger than 2 years.3 However, in some 
countries, this decrease was mitigated by an increased 
incidence of invasive pneumococcal disease caused 
by non-vaccine serotypes, most belonging to the 
extended-spectrum PCV.4 Soon after the switch from 
PCV7 to PCV13, many countries such as the USA, 
France, the UK, and Israel reported the expected 
pronounced decrease in invasive pneumococcal 
disease.5–8 The high eﬀ ectiveness of the PCV10 
vaccine has also been shown in Finland for invasive 
pneumococcal disease and clinically suspected invasive 
pneumococcal disease.9 
These results led to PCVs being classiﬁ ed among the 
more potent available vaccines: in the USA, 55 000 deaths 
from pneumococcus-related diseases in children were 
prevented by PCVs between 2001 and 2013.10 However, 
in developed countries, which beneﬁ t from favourable 
living conditions and well organised health-care systems, 
the early (and sustained) assessment of PCV performance 
is helped by active and well established surveillance of 
invasive pneumococcal disease. The burden of invasive 
pneumo coccal disease remains highest in low-income 
countries. Some had introduced PCVs through the 
GAVI Alliance with a small self-ﬁ nanced contribution. 
However, little published evidence is available about the 
eﬀ ect of PCVs on invasive pneumococcal disease in this 
context, because of the challenges in surveillance. 
In The Lancet Infectious Diseases, Grant Mackenzie 
and colleagues report the results of a well designed 
population-based active and standardised surveillance 
study for invasive pneumococcal disease in 
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The Gambia before and after PCV implementation 
(PCV7 in 2009 and PCV13 in 2011).11 Apart from the 
reported expected ﬁ ndings, of signiﬁ cance is the 
admirable eﬀ ort by the authors to do such a study by 
rigorously standardising the clinical and laboratory 
aspects of the surveillance. The project involved 
several teams, with conceptualisation beginning about 
10 years ago. The authors investigated 14 650 patients 
and identiﬁ ed 320 cases of invasive pneumococcal 
disease, to do a robust assessment of the eﬀ ect 
of PCV13. Despite suboptimal PCV13 coverage, in 
children 2–23 months of age, the incidence of invasive 
pneumococcal disease fell by 55% (95% CI 30–71) 
and that of PCV13 serotype prevalence fell by 82% 
(95% CI 64–91). In older children (2–4 years of age), 
the incidence of invasive pneumococcal disease fell by 
56% (95% CI 25–75) owing to a 68% (95% CI 39–83) 
reduction in the prevalence of PCV13 serotypes, 
which suggests that a combination of direct and herd 
protection eﬀ ects were in force. 
All these results support the substantial beneﬁ t of 
PCVs introduced in African countries. However, two 
concerns draw our attention: ﬁ rst, the report of a slight 
increase in invasive pneumococcal disease incidence 
in all age groups (except adults) in 2014, and second, 
a signiﬁ cant increase in prevalence of non-PCV13 
serotypes, especially in children aged 2–59 months, in 
whom the incidence of invasive pneumococcal disease 
almost doubled. This potentially worrying result 
should be balanced by the fact that the serotypes that 
emerged are unlikely to be as invasive as those included 
in the PCVs.12 In the post-PCV13 era, the main non-
PCV13 serotypes that the authors reported in children 
2–59 months old were serotypes 12F, 10A, 15A, 35B, 
and 16F.11 A recent study showed that of the non-
PCV13 serotypes, only two—24F and 12F—had high 
disease potential in the PCV13 era.12 In Mackenzie and 
colleagues’ study in The Gambia, serotype 24F was rare 
(only two cases were reported) in the PCV13 era, so 
serotype 12F remained the only one with high disease-
causing potential.11 
Besides the reduced incidence of invasive pneumo-
coccal disease in developed countries, the spectrum 
and proﬁ le of invasive pneumococcal disease has 
changed following the changed serotype distribution, 
and the proportion of patients with underlying 
illnesses has increased.13 We have shown that patients 
with meningitis are infected more frequently with 
non-PCV13 serotypes than other serotypes, whereas 
serotypes implicated in pneumococcal pneumonia 
are usually PCV13 serotypes, especially 1, 7F, 19A, 
and 3.13 These results agree with those reported by 
Kaplan and colleagues,14 showing greater reduction 
in cases of pneumococcal bacteraemia, pneumonia, 
and mastoiditis than those of meningitis after PCV13 
introduction in eight children’s hospitals in the 
USA. Similarly, the data reported by Mackenzie and 
colleagues11 show that patients with meningitis were 
infected more frequently with non-PCV13 sero types 
than PCV13 serotypes (44·7% vs 26·3%), whereas for 
pneumonia, the rates were reversed (21·7% vs 56·1%).11 
This serotype distribution clearly explains the notable 
decrease in pneumonia cases and the slight fall in 
meningitis cases. With a more prolonged period after 
PCV13 introduction, the expected decrease in pneu-
monia cases will be substantial. 
This study has important implications for the 
introduction of PCVs in all African countries, where the 
rates of invasive pneumococcal disease remain around 
ten-fold higher than those in developed countries. How-
ever, maintenance of invasive pneumococcal disease 
surveillance is essential to clarify the role of PCVs in 
changing the serotype incidence, in view of the possible 
increase in invasive pneumococcal disease cases related 
to non-vaccine serotypes. 
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The elusive global burden of dengue 
Dengue has emerged in the past two decades as a 
rapidly growing and widespread public health problem, 
with over half of the world’s countries and people now 
at risk.1 In new estimates from the Global Burden of 
Disease study published in The Lancet Infectious Diseases, 
Jeﬀ rey Stanaway and colleagues2 suggest that dengue 
incidence has increased six-fold from 1990 to 2013, 
accompanied by much ﬂ atter mortality trends. Dengue 
is still regarded as a neglected disease,3 yet its incidence 
is increasing at an alarming rate, by contrast with 
declines in other neglected diseases.4 WHO estimates 
that 50 million to 100 million cases occur annually.5 In 
2012, however, formal modelling put the number of 
dengue infections as high as 390 million (95% credible 
interval 284 million–528 million), but included both 
inapparent and apparent cases.1 Their esti mated 
number of apparent cases (96 million, 95% credible 
interval 67 million–136 million) lies at the high end of 
the WHO estimates. 
Against this background, these new estimates 
from the Global Burden of Disease Study suggest a 
much lower number of cases for 2013: 58·4 million 
(95% uncertainty interval 23·6 million–121·9 million).2 
Why is it so diﬃ  cult to arrive at consistent estimates? 
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Figure: Dengue case fatality rates for 39 countries estimated to have at least ten dengue deaths and autochthonous transmission
Data from Stanaway and colleagues.2 CFR=case fatality rate.
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